Please login or register to print this page.

Clinical Articles, News & Views

Renal denervation to be evaluated

The real-world clinical use of a renal denervation system (Symplicity,™ Medtronic, Inc.), across multiple conditions, is to be evaluated by two clinical initiatives announced recently.

The Global SYMPLICITY Patient Registry will evaluate the impact of renal denervation in more than 5,000 patients alongside SYMPLICITY-HF, the first clinical trial to examine renal denervation in patients with chronic heart failure and renal impairment.

“These research initiatives represent part of Medtronic’s broad commitment to partner with the medical community to explore the use of renal denervation in a number of disease states characterised by hyperactive sympathetic nervous system drive,” said Sean Salmon, Senior Vice President and President, Coronary & Renal Denervation, Medtronic.

“Data from the Global SYMPLICITY Registry and the SYMPLICITY-HF clinical trial will build upon the substantial renal denervation data Medtronic has generated in patients with treatment-resistant hypertension to date.”

Published on: March 9, 2012

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.